Table 10Databases searched and inclusion/exclusion criteria

Electronic databasesAMED, BNI, CENTRAL, CINAHL, Embase, Medline, PsycINFO
Date searchedDatabase inception to March 2006; table of contents September 2004 to 5 May 2006
Study designRCT (efficacy, acceptability, tolerability, adverse events)
Observational study (adverse events)
Patient populationVaD/DLB/FTD/other dementias (subcortical, mixed dementias)/MCI/Down’s syndrome and other learning disabilities plus dementia
InterventionsDonepezil, galantamine, rivastigmine, memantine
Outcomes

Improvement on a score of a cognitive function test (for example, MMSE, ADAS-Cog)

Improvement on ADL test score (for example, ADL, IADL, BGP, NOSGER)

Reduction in carer stress (for example, CBS)

Delay in time to 24-hour care

Subjective improvement in quality of life

Global rating scale (for example, CIBC-Plus, CGIC, SCAG, GDS)

Side effects (for example, ESRS, TESS, targeting abnormal kinetic effects)

Leaving the study early

From: 7, THERAPEUTIC INTERVENTIONS FOR PEOPLE WITH DEMENTIA – COGNITIVE SYMPTOMS AND MAINTENANCE OF FUNCTIONING

Cover of Dementia
Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care.
NICE Clinical Guidelines, No. 42.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2007.
Copyright © 2007, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.